14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
XLV vs XBI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Health Care Select Sector SPDR Fund (XLV) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (48.1/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XLV trades at $177.24 (N/M Forward P/E, N/A operating margin) versus XBI at $140.18 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. XLV 48.1/100 HOLD), XLV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: XLV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.7); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLV vs XBI. Trailing 12-month operating profitability (XLV N/A vs XBI N/A) and valuation multiples (XLV N/M vs XBI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XLV vs XBI Key Questions & Quantitative Answers
As of Nov 20, 2026, Health Care Select Sector SPDR Fund (XLV) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (48.1/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XLV trades at $177.24 (N/M Forward P/E, N/A operating margin) versus XBI at $140.18 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. XLV 48.1/100 HOLD), XLV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: XLV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.7); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XLV and XBI split Growth & Scale metrics: XLV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XBI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XLV generates N/A in USD-normalized revenue versus N/A for XBI. In operating R&D and SG&A reinvestment, XLV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBI.
XLV and XBI trade at balanced relative valuation multiples. XLV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XBI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XLV (N/A ROE) versus XBI (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XLV carries 13.0% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.26β · 22% Vol realized risk). By comparison, XBI carries 58.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.17β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.